Skip to main content
TanyaKanker
Phase 3NCT07185997Lung Cancer
Targeted therapy
Targeted therapy

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Targeted therapy

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07185997Not verified

Four separate status dimensions

  • RegistryRecruiting in registry
  • SiteNot verifiedUnknown, so no conclusion can be drawn.
  • International accessUnknownUnknown, so no conclusion can be drawn.
  • Patient matchNot assessedUnknown, so no conclusion can be drawn.

Three statuses often treated as one

A recruiting registry status does not mean a patient can immediately join this study. These three questions are answered by different parties.

  1. Registry status

    Stated by the study record owner: whether the study is listed as recruiting. It does not state whether a site is active.

  2. Site status

    Stated by the facility: whether the site is running this study now. TanyaKanker has not verified this.

  3. International access

    Stated by facility policy: whether patients from outside the local country can be accepted.

Why this appears

Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.

What to verify

  • • Acceptance of patients from outside the local country has not been verified.
  • • We have not verified that the study site is actively running this study.
  • • Eligibility is determined by the study team, not by registry data.
  • • This record has never been directly verified by us.
Upload Medical ReportsRegistry ClinicalTrials.gov

Preliminary screening only shows overlap and data needs. Eligibility is determined by the study team.

Why this study may be relevant

  • This study is recorded for Lung Cancer, the same cancer group you are exploring.
  • The study requirements mention marker EGFR, so your molecular result is relevant to discuss.
  • Recorded interventions: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice.
  • The study is in Phase 3 according to registry data.
  • Locations are recorded in United States, Australia, Canada.

The relevance above is assembled from registry data, not from an eligibility judgement.

Study basis

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Sponsor
ArriVent BioPharma, Inc.
Registry
ClinicalTrials.gov NCT07185997
Phase
Phase 3

Cancer and markers

Lung CancerEGFR

Recorded interventions

FirmonertinibEGFR-TKI inhibitor based on investigator's choice

Study locations

  • St. Jude Medical Center

    Fullerton

    United States

  • USC/Norris Comprehensive Cancer Center

    Los Angeles

    United States

  • Providence St. Joseph Hospital

    Orange

    United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento

    United States

  • UCSF Medical Center-Mission Bay

    San Francisco

    United States

Showing 5 of 139 locations recorded in the registry.

What we know

  • Registry status: Recruiting.
  • Phase 3 with sponsor ArriVent BioPharma, Inc..
  • 139 locations recorded in the registry.
  • Registry data updated 2026-10-14.

What we do not know yet

  • Whether the site accepts patients from outside the local country.
  • Whether the site is actively running the study now.
  • Which cost components are borne by participants.
  • Which documents the sponsor requires.

Main eligibility factors from the registry

  • Protocol sex: all
  • Protocol minimum age: 18 Years
  • Complete eligibility criteria appear only in the study protocol and must be assessed by the study team.

This summary is taken from registry data. Complete criteria live in the study protocol and must be assessed by the study team.

Documents that may be needed

  • Disease history summary from the treating doctor
  • Most recent pathology report
  • Molecular marker report if available
  • Most recent imaging results
  • List of current medicines

This is a general frame, not the sponsor's official list.

Upload Medical Reports

Updates and sources

Registry update
2026-10-14
Retrieved by TanyaKanker
2026-10-16
Last verified
Never
Contact status
Not contacted

Data comes from the public ClinicalTrials.gov registry of the US National Library of Medicine. Registry facts are public data; interpretation about international patient access, cost, and site readiness does NOT come from the registry and is marked unverified.

https://clinicaltrials.gov/study/NCT07185997

Treatment categories

Cost

NOT VERIFIED

Not verified. The public registry does not include cost details for international patients and does not state payment coverage.

This information is not a diagnosis or a medical recommendation. Decisions remain with your medical team.

Not a diagnosis and not final medical advice. Must be reviewed by a doctor.

Other studies in a similar group

Check preliminary match for your case

This screening shows overlap between your summary and the study, plus data that still needs to be completed. Eligibility remains the study team's decision.

Consult via WhatsAppUpload Medical Reports

After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.

Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.

Next steps

These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.

To check

What you can do

  • Upload medical reports

    Build a case summary in twelve steps

    Reason: Often the most useful next step after reading this page

  • Request a second opinion

    Review of the treatment plan

    Reason: Relevant when a treatment plan is being considered

  • Consult a navigator

    A request is recorded with this page context

    Reason: For asking the next step directly

Recently updated

Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.

Prepare for your next consultation

Use the free six-question tool to prepare questions for your doctor.

Start free · 6 questionsContact a navigatorSaved pages